HCPCS code Q4122: DermACELL billing, modifiers, and fee schedule

Key takeaways

HCPCS code Q4122 describes DermACELL, DermACELL AWM, and DermACELL AWM Porous, an acellular dermal matrix billed per square centimeter of product applied.

For 2026, CMS pays Q4122 as an incident-to supply rather than an ASP-priced biological, at 3.81 practice expense RVUs per square centimeter.

Locality GPCI adjustment moves that payment from roughly $109 to about $183 per square centimeter, so the national figure is only a planning number.

Every Medicare claim line for Q4122 carries either JW for discarded product or JZ for none, and Q7 through Q9 do not apply.

Practice management software like Pabau tracks HCPCS codes, claim submissions, and payer responses across every location your wound care team bills from.

HCPCS code Q4122 is the Level II code for DermACELL, DermACELL AWM, and DermACELL AWM Porous, billed per square centimeter of product applied. It is a skin substitute code, so Medicare pays it alongside the CPT code for the application procedure rather than on its own.

The biggest change for 2026 is how Medicare prices it. The code moved off ASP-based biological payment and onto the physician fee schedule as an incident-to supply. This guide covers the official description, the 2026 fee schedule, unit calculation, and the modifiers Medicare expects. It also covers ICD-10 pairing, place of service, documentation, prior authorization, and the related skin substitute Q-codes.

HCPCS code Q4122: Description and product overview

HCPCS code Q4122 is a Level II HCPCS Q-code maintained by the Centers for Medicare and Medicaid Services (CMS). Q-codes are temporary codes assigned to non-physician services and products not covered by the standard CPT code set. Q4122 covers three product variants manufactured by LifeNet Health, all billed at the same rate per square centimeter of product applied.

DermACELL, DermACELL AWM, and DermACELL AWM Porous: What the variants mean

All three products are acellular dermal matrices, meaning the cellular components have been removed while preserving the extracellular matrix scaffold that supports tissue regeneration. The variants differ in porosity and intended clinical use.

All three variants bill under the same HCPCS code Q4122. Billing staff do not need to select a different code based on which variant was applied. The operative or clinical note should still record which specific product was used, because auditors ask.

2026 Medicare fee schedule and reimbursement rates

Medicare pays Q4122 under the CMS Physician Fee Schedule as an incident-to supply, at 3.81 practice expense RVUs per square centimeter. No work RVUs and no malpractice RVUs attach to the code. Multiply those 3.81 RVUs by your locality’s practice expense GPCI and by the 2026 conversion factor of $33.4009 to get the allowed amount.

That works out to roughly $127 per square centimeter before any geographic adjustment. Actual payment runs from about $109 in a low-GPCI locality such as Arkansas to about $183 in San Jose. Treat the national figure as a planning number, not the amount your MAC will pay.

Place of service matters as much as locality. Q4122 carries a facility NA indicator, so the physician is paid for the product only in non-facility settings. Apply it in a hospital outpatient department and the product is paid to the hospital under OPPS instead.

Rates change with each annual rule, so confirm the current figure for your locality before you set a charge. The CMS list of CPT/HCPCS codes also tells you whether Q4122 sits on your MAC’s covered code list for the current year.

Q4122 billing guidelines

Q4122 billing follows quantity rules tied to the physical product applied. Incorrect unit calculations are the most common source of claim errors for skin substitute Q-codes. Your claims management software should enforce these rules before the claim leaves the practice.

• Unit calculation: Bill one unit of Q4122 for each square centimeter of DermACELL applied, not for the wound size. Apply a 10 sq cm sheet to a 10 sq cm wound and you bill 10 units. If only part of a sheet goes on, bill the portion actually applied.
• Product size documentation: The operative or treatment note must record the size of the product used and the size of the wound bed. Both measurements are required for audit defense.
• Companion CPT code: Q4122 is billed alongside a wound care or surgical application CPT code, such as a debridement or graft application code. Q4122 covers the product; the CPT code covers the application procedure.
• Do not unbundle: Bill one line for Q4122 per session, with the total square centimeters as the quantity. Do not submit separate Q4122 lines for different wound sites on the same visit unless the payer’s policy allows it.
• Quantity limits: Some MACs apply maximum quantity limitations per application session. Check your MAC’s LCD for applicable limits before submitting high-unit claims.

Applicable modifiers for Q4122

Modifier selection for Q4122 affects Medicare compliance and audit risk directly. Waste reporting is the part that trips practices up, because one of two modifiers belongs on every claim line. Q7, Q8, and Q9 do not apply here. Those report Class A, B, and C findings on routine foot care claims, not on skin substitutes.

JW/JZ modifier rule: CMS mandated waste reporting for Medicare Part B drugs and biologics. MACs apply the same requirement to skin substitute products, Q4122 included. Every Q4122 claim line must carry either JW or JZ. Verify current applicability with your own MAC, since requirements vary by jurisdiction. Building MAC-level modifier guidance into your medical billing compliance checks keeps this from becoming a recurring denial.

Covered ICD-10 diagnosis codes for Q4122

Q4122 must be billed with a covered ICD-10 diagnosis code that establishes medical necessity. Your MAC’s Local Coverage Determination (LCD) for skin substitute products lists the approved codes. The table below reflects categories accepted across most MACs, though a jurisdiction-specific LCD may restrict or expand the list. Our ICD-10-CM code index covers these diagnosis families in more detail.

Always verify covered diagnoses against your MAC’s current LCD before submitting. The AAPC’s HCPCS code lookup provides crosswalk references, but the MAC LCD is the controlling document for coverage decisions.

Place of service for Q4122

The place of service (POS) code decides who gets paid for the product, not just how much. Because Q4122 carries a facility NA indicator, a physician claim submitted with a facility POS returns no separate product payment. Selecting the wrong POS code therefore produces either a technical denial or a write-off nobody expected.

Documentation requirements for Q4122

Inadequate documentation is the leading cause of Q4122 denials on post-payment audit. Skin substitute products carry a high unit cost, so MACs scrutinize DermACELL claims closely. The note has to establish medical necessity, confirm the product used, and justify the quantity billed.

• Wound measurements: Record wound dimensions (length x width, or total area in sq cm) at the time of application. This must match the billed quantity of Q4122 units.
• Product identification: Document which DermACELL variant was used (DermACELL, DermACELL AWM, or DermACELL AWM Porous), including the product lot number and size applied.
• Chronicity evidence: Most LCDs require documentation that the wound has failed to respond to standard care for a minimum period, often 30 days. Include wound measurement history showing lack of adequate healing.
• Prior treatment failure: Document what conservative treatments were tried before the skin substitute went on. Examples include compression therapy for venous ulcers and offloading for diabetic foot ulcers.
• Clinical indication: The diagnosis code must be supported by the clinical documentation. The physician note should state the wound type, location, and reason the skin substitute is medically necessary.
• Modifier justification: When you report JW, document the size of product opened against the size applied. When you report JZ, the note should still show that the whole sheet went onto the wound.

A documentation checklist applied at the point of care prevents the omissions behind most denials. Keep the records complete, retrievable, and defensible, because the audit usually arrives long after the encounter.

Prior authorization and payer coverage

Medicare does not typically require prior authorization for Q4122 when the claim meets LCD coverage criteria. Commercial payers are a different matter. Many require prior authorization for skin substitute products, and missing it is one of the most expensive mistakes in wound care billing.

• Medicare (Part B): No prior authorization required in most jurisdictions, but the claim must satisfy all LCD medical necessity criteria at the time of submission. Retrospective denials still occur when documentation is inadequate.
• Commercial payers (e.g. BlueCross BlueShield): Prior authorization is commonly required for skin substitute products. BlueCross BlueShield’s medical policy for bioengineered skin substitutes addresses authorization requirements for codes including Q4122. Requirements vary by plan and state.
• Medicare Advantage plans: MA plans may impose authorization requirements not present in traditional Medicare. Always verify with the specific plan before applying the product.
• LCD jurisdiction check: Each MAC publishes its own LCD for skin substitutes. Search the CMS Medicare Coverage Database for your MAC’s LCD to confirm which diagnoses and products are covered in your region.

Related HCPCS skin substitute codes

Q4122 is one of dozens of Q-codes assigned to specific skin substitute products. When the product applied is not DermACELL or one of its variants, a different Q-code applies. Selecting the wrong code for the product actually used is an error auditors flag consistently.

The table below lists commonly used neighboring codes, so billing staff can find the correct Q-code when a different product is on hand. Watch the billing unit column in particular, since Q4114 is priced per cc rather than per square centimeter.

2026 CMS changes affecting skin substitute billing

CMS finalized payment policy changes for skin substitutes that took effect in 2026, and they reach further than most annual updates. Billing built on pre-2026 rules produces systematic errors, so the changes below belong in your charge capture setup and your coder training.

• Reclassification away from ASP pricing: Q4122 was paid as a separately payable biological under the ASP methodology in 2025. For CY2026 it moved off ASP-based pricing and onto the physician fee schedule as an incident-to supply. The code now carries 3.81 practice expense RVUs, with no work or malpractice RVUs.
• Product cost folded into the procedure: CMS has moved toward paying for skin substitute products through the application procedure rather than separately by Q-code. This changes how facility settings recover product cost in particular.
• LCD policy updates: MACs have updated their LCDs in response to the 2026 rule changes. Coverage criteria, approved product lists, and documentation requirements may have changed in your jurisdiction. Review your MAC’s current LCD before submitting Q4122 claims.
• Action required: Contact your MAC or check the CMS Medicare Coverage Database for the current LCD and coverage article covering skin substitutes in your region. Confirm that Q4122 remains on your MAC’s covered product list under the revised policy.

Skin substitute policy is still moving, so confirm 2026 details through official CMS channels or your compliance team before filing under the new rules. The reclassification also changes what a reasonable charge looks like, which is worth revisiting with your fee schedule owner.

How Pabau keeps Q4122 claims accurate before they go out

Most wound care practices find a Q4122 unit error after the remittance comes back. The product size sits in the operative note and the billed quantity sits in the claim. Nobody compares the two until a denial forces it.

Pabau keeps the clinical note and the claim in the same patient record. Your coder sees the documented product size next to the units on the claim line. JW or JZ gets set before submission rather than after an audit letter.

That shortens the rework cycle on your highest-value claim lines. When a Q4122 claim is questioned, the wound measurements, product lot, and prior treatment history are already on the record. Your team builds the appeal from one chart.

Manage wound care billing from one platform

Pabau supports HCPCS code tracking, claims submission, and documentation workflows for wound care and skin practices. See how it works.

Book a demo

Conclusion

Q4122 rewards precision in three places. Bill the square centimeters you applied, put JW or JZ on every line, and hold documentation your MAC’s LCD accepts. That test applies on the day of application, not on the day of the audit.

The 2026 reclassification adds a fourth. Check what the code now pays in your own locality before the product is ordered. The national figure and your allowed amount can differ by more than $50 per square centimeter. On a 20 sq cm application, that difference decides whether the case is profitable.

Book a demo to see how Pabau tracks HCPCS units, modifiers, and payer responses across a wound care caseload.

Continue your research

Applying Apligraf instead of DermACELL? HCPCS code Q4101 covers the unit rules, modifiers, and coverage criteria for that product.

Billing GRAFTJACKET on the same wound care caseload? HCPCS code Q4107 sets out how that acellular dermal matrix is coded and documented.

Need to reconcile what a payer actually paid on a Q-code line? Electronic remittance advice explains how ERA files match payments back to submitted HCPCS charges.

Chasing authorizations before the product goes on? The prior authorization process walks through what commercial payers ask for and how long each step takes.

Frequently asked questions